ArticleMolecular pharmaceutics2010
Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.
Article in Molecular pharmaceutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Encapsulation of doxorubicin in magnesium acetate liposomes as a pH-sensitive drug carrier for tumor therapy.iScience · 2025Article
- Physicochemical Stimulus-Responsive Systems Targeted with Antibody Derivatives.Current molecular medicine · 2024Review
- Synergy effects of copper ion in doxorubicin-based chelate prodrug for cancer chemo-chemodynamic combination therapy.Drug delivery · 2023Article
- Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review.RSC advances · 2023Review
- CuFeSACS applied materials & interfaces · 2023Article
- The Critical Role of 12-Methyl Group of Anthracycline Dutomycin to Its Antiproliferative Activity.Molecules (Basel, Switzerland) · 2022Article
- Synergic fabrication of pembrolizumab loaded doxorubicin incorporating microbubbles delivery for ultrasound contrast agents mediated anti-proliferation and apoptosis.Drug delivery · 2021Article
- The Effective Combination between 3D Cancer Models and Stimuli-Responsive Nanoscale Drug Delivery Systems.Cells · 2021Review
- Ultrasound-Responsive Nanocarriers in Cancer Treatment: A Review.ACS pharmacology & translational science · 2021Review
- Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Multifunctional and stimuli-responsive nanocarriers for targeted therapeutic delivery.Expert opinion on drug delivery · 2021Review
- Overcoming Multidrug Resistance in Bacteria Through Antibiotics Delivery in Surface-Engineered Nano-Cargos: Recent Developments for Future Nano-Antibiotics.Frontiers in bioengineering and biotechnology · 2021Review
- Remote loading paclitaxel-doxorubicin prodrug into liposomes for cancer combination therapy.Acta pharmaceutica Sinica. B · 2020Article
- Tumor-specific delivery of gemcitabine with activatable liposomes.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Development and Characterization of the Solvent-Assisted Active Loading Technology (SALT) for Liposomal Loading of Poorly Water-Soluble Compounds.Pharmaceutics · 2019Review
- Combining activatable nanodelivery with immunotherapy in a murine breast cancer model.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Polymeric perfluorocarbon nanoemulsions are ultrasound-activated wireless drug infusion catheters.Biomaterials · 2019Article
- Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.Journal of controlled release : official journal of the Controlled Release Society · 2017Article
- Intracellular trafficking of a pH-responsive drug metal complex.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Repeated administration of chemotherapeutics is typically required for the effective treatment of highly aggressive tumors and often results in systemic toxicity. We have created a copper-doxorubicin complex within the core of liposomes and applied the resulting particle in multidose therapy. Copper and doxorubicin concentrations in the blood pool were similar at 24 h (∼40% of the injected dose), indicating stable circulation of the complex. Highly quenched doxorubicin fluorescence remained in the blood pool over tens of hours, with fluorescence increasing only with the combination of liposome disruption and copper trans-chelation. At 48 h after injection, doxorubicin fluorescence within the heart and skin was one-fifth and one-half, respectively, of fluorescence observed with ammonium sulfate-loaded doxorubicin liposomes. After 28 days of twice per week doxorubicin administration of 6 mg/kg, systemic toxicity (cardiac hypertrophy and weight and hair loss) was not detected with the copper-doxorubicin liposomes but was substantial with ammonium sulfate-loaded doxorubicin liposomes. We then incorporated two strategies designed to enhance efficacy, mTOR inhibition (rapamycin) to slow proliferation and therapeutic ultrasound to enhance accumulation and local diffusion. Tumor accumulation was ∼10% ID/g and was enhanced approximately 2-fold with the addition of therapeutic ultrasound. After the 28-day course of therapy, syngeneic tumors regressed to a premalignant phenotype of ∼(1 mm)(3) or could not be detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.